Amedeo Smart

Free Medical Literature Service

 

Amedeo

Antiretroviral Therapy
  Free Subscription

Articles published in
J Acquir Immune Defic Syndr
    September 2026
  1. BUCCHERI R, Spinelli MA, Saberi P, Neilands TB, et al
    At-Home Point-of-Care Urine Tenofovir Testing for Adherence Monitoring: Feasibility and Comparison with Adherence Metrics in Dried Blood Spots.
    J Acquir Immune Defic Syndr. 2026 Sep 25. doi: 10.1097/QAI.0000000000003953.
    >> Share

  2. FERRARIS CM, D'Avanzo PA, Schiavoni NF, Knox J, et al
    Longitudinal Performance of Self-Reported ART Adherence Compared With Tenofovir Diphosphate in Dried Blood Spots in South Africa.
    J Acquir Immune Defic Syndr. 2026 Sep 16. doi: 10.1097/QAI.0000000000003975.
    >> Share

  3. ADEOJO LW, Pauls C, Swaim D, Kumar P, et al
    Pharmacokinetics/Pharmacodynamics, Safety, and Tolerability of Rivaroxaban with Cobicistat or Darunavir/Cobicistat in Healthy Participants.
    J Acquir Immune Defic Syndr. 2026 Sep 4. doi: 10.1097/QAI.0000000000003971.
    >> Share

  4. VELLOZA J, Adler A, Chakravarty D, Glidden DV, et al
    Associations between self-reported PrEP use and short and long-term pharmacologic metrics of PrEP adherence among Kenyan women.
    J Acquir Immune Defic Syndr. 2026 Sep 4. doi: 10.1097/QAI.0000000000003967.
    >> Share

  5. MOYLE G, Radtchenko J, Gruber J, Dunbar M, et al
    Weight trajectories in virally suppressed people with HIV compared to matched people without HIV, and predictors of weight gain: a 3-year cohort study from the US TRIO Healthcare Network.
    J Acquir Immune Defic Syndr. 2026 Sep 2. doi: 10.1097/QAI.0000000000003932.
    >> Share

    August 2026
  6. ABDALLA S, Lallemant M, Compagnucci A, Nardone A, et al
    Pharmacokinetic modeling to support WHO-weight band dosing of a new pediatric darunavir/ritonavir (120/20 mg) fixed-dose combination tablet for children at least 3 years old and weighing 10 to less than 35 kg.
    J Acquir Immune Defic Syndr. 2026 Aug 21. doi: 10.1097/QAI.0000000000003956.
    >> Share

  7. NYAKATO P, Euvrard J, Chinogurei C, Boulle A, et al
    HIV care interruptions during the first year of antiretroviral therapy among adolescents and young adults living with HIV aged 15-24 years in Khayelitsha, South Africa.
    J Acquir Immune Defic Syndr. 2026 Aug 6. doi: 10.1097/QAI.0000000000003948.
    >> Share

    June 2026
  8. OSMAN F, Yende-Zuma N, Zewotir T, Naicker N, et al
    Comparing clinical and cytokine profiling of genital inflammation as predictors of HIV acquisition in women.
    J Acquir Immune Defic Syndr. 2026 Jun 12. doi: 10.1097/QAI.0000000000003915.
    >> Share

    March 2026
  9. VANDERVEEN LA, Selzer L, Chang S, Li J, et al
    Resistance Analysis of Weekly Islatravir Plus Lenacapavir in People with HIV at 48 Weeks.
    J Acquir Immune Defic Syndr. 2026 Mar 26. doi: 10.1097/QAI.0000000000003873.
    >> Share

  10. BODLEY N, Govender K, Moodley P, Samsunder N, et al
    Association between pharmacological tenofovir adherence measures and subsequent 24-week viral load outcomes for people with HIV in South Africa.
    J Acquir Immune Defic Syndr. 2026 Mar 26. doi: 10.1097/QAI.0000000000003866.
    >> Share

  11. OWOR M, Baltrusaitis K, DeMarrais P, Frenkel LM, et al
    Associations of Plasma and Breast Milk HIV RNA and Tenofovir Concentrations with Risk of Postnatal HIV Transmission during Breastfeeding Among Women with and without ARV Exposure.
    J Acquir Immune Defic Syndr. 2026 Mar 16. doi: 10.1097/QAI.0000000000003863.
    >> Share

    February 2026
  12. MCCORMACK S, Dunn D, Kusemererwa S, Munseri P, et al
    A comparison of F/TAF and F/TDF as HIV pre-exposure prophylaxis in a predominantly cisgender women population in East and South Africa: a randomised, factorial, non-inferiority trial.
    J Acquir Immune Defic Syndr. 2026 Feb 6. doi: 10.1097/QAI.0000000000003845.
    >> Share

  13. NDLOVU N, Plagianos M, Palanee-Phillips T, Reddy K, et al
    Adherence, Preference, and Acceptability of an Overencapsulated Dual Prevention Pill for HIV and Pregnancy Prevention Among Women in Johannesburg, South Africa.
    J Acquir Immune Defic Syndr. 2026;101:141-152.
    >> Share

    December 2025
  14. BALTRUSAITIS K, Tierney C, Fowler MG, Owor M, et al
    Postpartum maternal monitoring for renal safety related to tenofovir exposure during breastfeeding in the PROMISE 1077BF randomized trial.
    J Acquir Immune Defic Syndr. 2025 Dec 31. doi: 10.1097/QAI.0000000000003829.
    >> Share

  15. KANG M, Umbleja T, Avihingsanon A, Cardoso SW, et al
    Hepatitis B Vaccination Histories in Persons with HIV Needing Revaccination.
    J Acquir Immune Defic Syndr. 2025 Dec 26:10.1097/QAI.0000000000003828.
    >> Share

  16. TIEN D, Chandiwana N, Shazi G, Chen G, et al
    Dolutegravir-based therapy, diet, physical activity and weight gain: a 48-week prospective cohort in South Africa.
    J Acquir Immune Defic Syndr. 2025 Dec 2. doi: 10.1097/QAI.0000000000003812.
    >> Share

  17. MPOFU R, Chandiwana N, Sokhela S, Moorhouse M, et al
    The Effect of Rifampicin on the Plasma and Intracellular Pharmacokinetics of Tenofovir Alafenamide Fumarate in Participants with HIV-associated Tuberculosis.
    J Acquir Immune Defic Syndr. 2025 Dec 2. doi: 10.1097/QAI.0000000000003810.
    >> Share

    November 2025
  18. NGUYEN T, Chae JW, Ziemba L, Coletti A, et al
    Breast Milk Transfer and Infant Exposures to Dolutegravir, Tenofovir, and Tenofovir Alafenamide: Results from IMPAACT 2010/VESTED.
    J Acquir Immune Defic Syndr. 2025 Nov 6. doi: 10.1097/QAI.0000000000003796.
    >> Share

    October 2025
  19. MAGONGO EN, Hast M, Nabitaka V, Nakanwagi M, et al
    Low Levels of Clinically Significant Drug Resistance Mutations to Dolutegravir amongst Children Living with HIV Failing on First-line Antiretroviral Therapy in Uganda.
    J Acquir Immune Defic Syndr. 2025 Oct 23. doi: 10.1097/QAI.0000000000003784.
    >> Share

  20. ORKIN C, Kuritzkes DR, Katlama C, Su FH, et al
    Doravirine Resistance Patterns Identified through Week 192 in the DRIVE-FORWARD and DRIVE-AHEAD Phase 3 Clinical Trials.
    J Acquir Immune Defic Syndr. 2025 Oct 23. doi: 10.1097/QAI.0000000000003787.
    >> Share

  21. HSUE PY, Behrens GMN, Xu ZJ, Zhao Y, et al
    Cardiovascular Risk Assessment Using the Atherosclerotic Cardiovascular Disease (ASCVD) Risk Score Model After Continuing or Switching to a Doravirine-Based HIV Treatment Regimen.
    J Acquir Immune Defic Syndr. 2025 Oct 13. doi: 10.1097/QAI.0000000000003778.
    >> Share

    September 2025
  22. MELNYCHUK S, Green K, Ejeckam C, Adesina A, et al
    HIV drug resistance among key populations in Nigeria: Insights from the 2020 integrated biological and behavioural surveillance survey.
    J Acquir Immune Defic Syndr. 2025 Sep 11. doi: 10.1097/QAI.0000000000003763.
    >> Share

    August 2025
  23. D'ANTONI ML, Boopathy AV, Andreatta K, Chang S, et al
    HIV-1 Resistance Analysis of Participants With HIV-1 and Hepatitis B Receiving Bictegravir/Emtricitabine/Tenofovir Alafenamide or Dolutegravir Plus Emtricitabine/Tenofovir Disoproxil Fumarate Through the Open-Label Extension of the ALLIANCE Study.
    J Acquir Immune Defic Syndr. 2025 Aug 26. doi: 10.1097/QAI.0000000000003749.
    >> Share

  24. MADLALA HP, Jao J, Roussos G, Mendham AE, et al
    Gluteal adipose tissue mitochondrial respiration and insulin sensitivity in pregnant South African women living with HIV on Tenofovir-Lamivudine-Dolutegravir.
    J Acquir Immune Defic Syndr. 2025 Aug 26. doi: 10.1097/QAI.0000000000003755.
    >> Share

  25. QIAN Y, Comulada WS, Hidalgo MA, Lee SJ, et al
    Depression improves the predictive accuracy of the VACS Index 2.0 for all-cause mortality among sexual minority men living with HIV in the Multicenter AIDS Cohort Study.
    J Acquir Immune Defic Syndr. 2025 Aug 26. doi: 10.1097/QAI.0000000000003752.
    >> Share

  26. BOOPATHY AV, D'Antoni ML, Andreatta K, Chang S, et al
    Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Participants with Preexisting K65R/N in HIV-1 in Phase 2/3/3b Clinical Trials.
    J Acquir Immune Defic Syndr. 2025 Aug 8. doi: 10.1097/QAI.0000000000003742.
    >> Share

  27. NUTT CT, Muyindike WR, Nanfuka V, Komukama N, et al
    Factors Associated with Incomplete Adherence to Dolutegravir-Based Antiretroviral Therapy in Southwestern Uganda.
    J Acquir Immune Defic Syndr. 2025 Aug 4. doi: 10.1097/QAI.0000000000003735.
    >> Share

    July 2025
  28. CABELLO-UBEDA A, Lopez Bernardo de Quiros JC, Mena A, Torralba M, et al
    Dolutegravir (DTG) + lamivudine (3TC) in antiretroviral-naive adults with HIV with and without genotypic resistance testing results. 96-Week effectiveness and tolerability of REDOLA study.
    J Acquir Immune Defic Syndr. 2025 Jul 17. doi: 10.1097/QAI.0000000000003721.
    >> Share

    June 2025
  29. YAO TJ, Zhang J, Malee K, Smith R, et al
    Prenatal Antiretroviral Exposure and Concomitant Neurodevelopmental Problems among 5-year-old Children who are HIV-Exposed and Uninfected.
    J Acquir Immune Defic Syndr. 2025 Jun 24. doi: 10.1097/QAI.0000000000003720.
    >> Share

  30. ANDERSON PL, Coppinger C, Cottrell ML, Marzinke MA, et al
    Recommendations for interpreting intraerythrocytic tenofovir-diphosphate and emtricitabine-triphosphate for PrEP adherence assessment.
    J Acquir Immune Defic Syndr. 2025 Jun 19. doi: 10.1097/QAI.0000000000003715.
    >> Share

  31. KAMPHUIS AEM, Waalewijn H, Wasmann RE, Bamford A, et al
    Pharmacokinetic data of atazanavir/ritonavir in second-line treatment of children living with HIV.
    J Acquir Immune Defic Syndr. 2025 Jun 16. doi: 10.1097/QAI.0000000000003704.
    >> Share

    May 2025
  32. SUDDERUDDIN H, Dang Z, Watson B, Atkinson K, et al
    Investigation of Integrase Inhibitor Resistance Mutations in gp41 in Clinical Samples.
    J Acquir Immune Defic Syndr. 2025 May 13. doi: 10.1097/QAI.0000000000003694.
    >> Share

    April 2025
  33. NDONGO FA, Tejiokem MC, Penda CI, Ndiang ST, et al
    IMMUNOLOGICAL AND VIROLOGIC OUTCOMES WITHIN TEN YEARS OF COMBINED ANTIRETROVIRAL THERAPY INITIATED BEFORE ONE YEAR OF AGE IN CAMEROONIAN CHILDREN WITH PERINATAL HIV.
    J Acquir Immune Defic Syndr. 2025 Apr 17. doi: 10.1097/QAI.0000000000003687.
    >> Share

  34. NAMPOTA-NKOMBA N, Buchwald A, Nyirenda OM, Mkandawire FA, et al
    Association between Maternal HIV and Adverse Birth Outcomes in the Era of Universal Antiretroviral Therapy in Malawi.
    J Acquir Immune Defic Syndr. 2025 Apr 17. doi: 10.1097/QAI.0000000000003685.
    >> Share

  35. MOROZOVA O, Conroy K, Riabokon S, Germanovich M, et al
    HIV Viral Rebound on Dolutegravir, Lopinavir and Efavirenz: National Program Data Analysis from Ukraine.
    J Acquir Immune Defic Syndr. 2025 Apr 7. doi: 10.1097/QAI.0000000000003676.
    >> Share

    March 2025
  36. ZHAO Y, Holtman M, Mudaly V, van Zyl G, et al
    Resistance to Dolutegravir in Treatment-experienced Patients in South Africa: A Retrospective Cohort Study.
    J Acquir Immune Defic Syndr. 2025 Mar 3. doi: 10.1097/QAI.0000000000003657.
    >> Share

  37. KISTAN G, Sebitloane M, Lombard C, Godlwana Z, et al
    Tenofovir Disoproxil Fumarate/Emtricitabine Prophylaxis Has No Effect on Bone Mineral Density and Bone Mineral Content in African Breastfeeding Women Receiving Pre-Exposure Prophylaxis for HIV.
    J Acquir Immune Defic Syndr. 2025;98:265-273.
    >> Share

    February 2025
  38. MBENGERANWA T, Ziemba L, Brummel SS, Johnston B, et al
    Bone mineral content, growth, and renal health of infants with perinatal exposure to maternal dolutegravir vs efavirenz and tenofovir disoproxil fumarate vs tenofovir alafenamide: the randomized IMPAACT 2010 (VESTED) trial.
    J Acquir Immune Defic Syndr. 2025 Feb 26. doi: 10.1097/QAI.0000000000003656.
    >> Share

  39. SCONZA R, Fernandes G, Bailey H, Peters H, et al
    Outcomes following prenatal exposure to raltegravir-containing antiretroviral therapy: a multi-cohort European study.
    J Acquir Immune Defic Syndr. 2025 Feb 25. doi: 10.1097/QAI.0000000000003645.
    >> Share

  40. PUTHANAKIT T, Aurpibul L, Lopez M, Wang M, et al
    Efficacy and Safety of the Two-Drug Regimen Dolutegravir/Lamivudine in Adolescents Living With HIV-1 Naive to Antiretroviral Therapy at 48 Weeks (DANCE): A Single-Arm, Open-label, Phase 3b Trial.
    J Acquir Immune Defic Syndr. 2025 Feb 24. doi: 10.1097/QAI.0000000000003655.
    >> Share

  41. ZHENG A, Fox MP, Greener R, Kileel EM, et al
    Initiation of Dolutegravir vs Efavirenz on Viral Suppression and Retention at 6-months: A Regression Discontinuity Design.
    J Acquir Immune Defic Syndr. 2025 Feb 6. doi: 10.1097/QAI.0000000000003642.
    >> Share

    January 2025
  42. DINIZ CP, Abdul-Massih S, Bagia C, Giguere R, et al
    Rectal Douche as HIV Pre-Exposure Prophylaxis for Receptive Anal Intercourse: An End User Tenofovir Powder Sachet Preparation Feasibility Study (DREAM-04).
    J Acquir Immune Defic Syndr. 2025 Jan 23. doi: 10.1097/QAI.0000000000003608.
    >> Share

  43. CALZA L, Colangeli V, Giglia M, Rigamonti C, et al
    EFFICACY AND SAFETY OF DOLUTEGRAVIR/LAMIVUDINE IN ANTIRETROVIRAL THERAPY-NAIVE PEOPLE LIVING WITH HIV-1 AND WITH HIGH-LEVEL VIREMIA.
    J Acquir Immune Defic Syndr. 2025 Jan 14. doi: 10.1097/QAI.0000000000003600.
    >> Share

  44. MOYLE G, Meng F, Wan H, Sklar P, et al
    Resolution of Neuropsychiatric Adverse Events After Switching to a Doravirine-Based Regimen in the Open-Label Extensions of the DRIVE-AHEAD and DRIVE-FORWARD Trials.
    J Acquir Immune Defic Syndr. 2025 Jan 3. doi: 10.1097/QAI.0000000000003599.
    >> Share

  45. L T, F M, D V, S B, et al
    Adherence and forgiveness of two modern ART regimens: lamivudine/dolutegravir and emtricitabine/tenofovir alafenamide/rilpivirine.
    J Acquir Immune Defic Syndr. 2025 Jan 2. doi: 10.1097/QAI.0000000000003594.
    >> Share

    December 2024
  46. GLASS DJ, Kinge M, Njuguna I, McGrath CJ, et al
    Poorer longitudinal growth among HIV exposed compared to unexposed infants in Kenya.
    J Acquir Immune Defic Syndr. 2024 Dec 27. doi: 10.1097/QAI.0000000000003592.
    >> Share

  47. BEESHAM I, Jaggernath M, Kriel Y, Hao J, et al
    Longitudinal changes in tenofovir and tenofovir-diphosphate concentrations among pregnant women using oral PrEP for HIV prevention: Findings from Durban, South Africa.
    J Acquir Immune Defic Syndr. 2024 Dec 20. doi: 10.1097/QAI.0000000000003586.
    >> Share

  48. TAN DHS, Antinori A, Eu B, Galindo Puerto MJ, et al
    Weight and metabolic changes with long-acting cabotegravir and rilpivirine or bictegravir/emtricitabine/tenofovir alafenamide.
    J Acquir Immune Defic Syndr. 2024 Dec 16. doi: 10.1097/QAI.0000000000003584.
    >> Share

  49. HASTIE E, Srivatsa MS, Gianella S, Cottrell M, et al
    Brief Report: Genital Microbiome, Inflammation, and Tenofovir Levels in Transgender Men and Cisgender Women Taking Oral PrEP.
    J Acquir Immune Defic Syndr. 2024;97:477-481.
    >> Share

    November 2024
  50. KISTAN G, Sebitloane M, Lombard C, Godlwana Z, et al
    Tenofovir Disoproxil Fumarate/Emtricitabine Prophylaxis Has No Effect on Bone Mineral Density and Bone Mineral Content in African Breastfeeding Women Receiving Pre-Exposure Prophylaxis for HIV.
    J Acquir Immune Defic Syndr. 2024 Nov 27. doi: 10.1097/QAI.0000000000003563.
    >> Share

  51. DEVANATHAN AS, Poliseno AJ, White NR, Schauer AP, et al
    A Cross-Biomeasure Study to Optimize Antiretroviral Adherence Estimation.
    J Acquir Immune Defic Syndr. 2024 Nov 21. doi: 10.1097/QAI.0000000000003570.
    >> Share

  52. POWIS KM, Pinilla M, McMorrow F, Stek A, et al
    Pharmacokinetics and safety of bictegravir in pregnant and postpartum persons with HIV and their infants.
    J Acquir Immune Defic Syndr. 2024 Nov 21. doi: 10.1097/QAI.0000000000003571.
    >> Share

    October 2024
  53. FINN B, Vanessa M, Xochitl LM, Emily P, et al
    Addressing methamphetamine use is essential to stopping HIV transmission.
    J Acquir Immune Defic Syndr. 2024 Oct 7. doi: 10.1097/QAI.0000000000003542.
    >> Share


  54. Brief Report: HIV-1 Resistance Analysis of Participants With HIV-1 and Hepatitis B Initiating Therapy With Bictegravir/Emtricitabine/Tenofovir Alafenamide or Dolutegravir Plus Emtricitabine/Tenofovir Disoproxil Fumarate: A Subanalysis of ALLIANCE Data
    J Acquir Immune Defic Syndr. 2024;97:202.
    >> Share

  55. LAZZARO A, Vai D, Barco A, Stroffolini G, et al
    Switching to Low Neurotoxic Antiretrovirals to Improve Neurocognition Among People Living With HIV-1-Associated Neurocognitive Disorder: The MARAND-X Randomized Clinical Trial.
    J Acquir Immune Defic Syndr. 2024;97:180-191.
    >> Share

  56. MASHETO G, Brummel SS, Ziemba L, Shepherd J, et al
    Markers of Maternal Bone and Renal Toxicity Through 50 Weeks Postpartum: IMPAACT 2010 (VESTED) Trial.
    J Acquir Immune Defic Syndr. 2024;97:172-179.
    >> Share

  57. MUJUGIRA A, Karungi B, Nakyanzi A, Bagaya M, et al
    Peer-Delivered HIV Self-Testing, Sexually Transmitted Infection Self-Sampling, and Pre-exposure Prophylaxis for Transgender Women in Uganda: A Randomized Trial.
    J Acquir Immune Defic Syndr. 2024;97:125-132.
    >> Share

  58. FAIRLIE L, Brummel S, Ziemba L, Coletti A, et al
    Subsequent pregnancies in the IMPAACT 2010/VESTED Trial: high rate of adverse outcomes in women living with HIV.
    J Acquir Immune Defic Syndr. 2024;97:150-155.
    >> Share

    August 2024
  59. JIAMSAKUL A, Rupasinghe D, Woolley I, Choi JY, et al
    HIV treatment outcomes after 10 years on ART in the TREAT Asia Observational Database (TAHOD) and Australian HIV Observational Database (AHOD).
    J Acquir Immune Defic Syndr. 2024 Aug 22. doi: 10.1097/QAI.0000000000003515.
    >> Share

  60. TUKEI VJ, Machekano R, Tchounga BK, Khumalo PN, et al
    Follow-up Outcomes of Children, Adolescents and Young People on Darunavir-Based Third-line Antiretroviral Therapy - Observational Cohort from Nine African Countries.
    J Acquir Immune Defic Syndr. 2024 Aug 1. doi: 10.1097/QAI.0000000000003498.
    >> Share

  61. BISHOP MD, Korutaro V, Boyce CL, Beck IA, et al
    Characterizing HIV drug resistance in cases of vertical transmission in the VESTED randomized antiretroviral treatment trial.
    J Acquir Immune Defic Syndr. 2024;96:385-392.
    >> Share

  62. D'ANTONI ML, Andreatta K, Chang S, Cox S, et al
    Brief Report: HIV-1 Resistance Analysis of Participants With HIV-1 and Hepatitis B Initiating Therapy With Bictegravir/Emtricitabine/Tenofovir Alafenamide or Dolutegravir Plus Emtricitabine/Tenofovir Disoproxil Fumarate: A Subanalysis of ALLIANCE Data
    J Acquir Immune Defic Syndr. 2024;96:380-384.
    >> Share

    June 2024
  63. IANNONE V, Ciccullo A, Moschese D, Giacomelli A, et al
    Treatment Experienced People Living With HIV switching to DOR/3TC/TDF in Outpatient Setting: Real-World Data on Tolerability and Cost Savings From an Italian Multicenter Cohort.
    J Acquir Immune Defic Syndr. 2024;96:e10-e11.
    >> Share

  64. JI C, Chen L, Kaypaghian M
    Effects of Combination of Ethanol With Ritonavir, Lopinavir or Darunavir on Expression and Localization of the ER-Associated Set Protein and Infection of HIV-1 Pseudovirus in Primary Human Cells.
    J Acquir Immune Defic Syndr. 2024;96:e6-e10.
    >> Share

    April 2024
  65. DORWARD J, Sookrajh Y, Lessells R, Bulo E, et al
    Viremia and HIV Drug Resistance Among People Receiving Dolutegravir Versus Efavirenz-Based First-Line Antiretroviral Therapy.
    J Acquir Immune Defic Syndr. 2024;95:e8-e11.
    >> Share

    March 2024
  66. QIAN Y, Zhang P, Wang L, Suo J, et al
    The association of intraocular efavirenz concentrations and HIV-1 viral load among persons with HIV.
    J Acquir Immune Defic Syndr. 2024 Mar 25. doi: 10.1097/QAI.0000000000003426.
    >> Share

  67. VAN HEERDEN JK, Meintjes G, Barr D, Zhao Y, et al
    Relationship Between Tenofovir Diphosphate Concentrations in Dried Blood Spots and Virological Outcomes After Initiating Tenofovir-Lamivudine-Dolutegravir as First-Line or Second-Line Antiretroviral Therapy.
    J Acquir Immune Defic Syndr. 2024;95:260-267.
    >> Share

    February 2024
  68. GRIESEL R, Banda CG, Zhao Y, Omar Z, et al
    PHARMACOKINETICS OF SINGLE VERSUS DOUBLE-DOSE DOLUTEGRAVIR AFTER SWITCHING FROM A FAILING EFAVIRENZ-BASED REGIMEN.
    J Acquir Immune Defic Syndr. 2024 Feb 15. doi: 10.1097/QAI.0000000000003402.
    >> Share

  69. DE WIT S, Bonnet F, Osiyemi O, Bisshop F, et al
    Durable Efficacy of Switching From a 3- or 4-Drug Tenofovir Alafenamide-Based Regimen to the 2-Drug Regimen Dolutegravir/Lamivudine in the TANGO Study Through Week 196.
    J Acquir Immune Defic Syndr. 2024 Feb 8. doi: 10.1097/QAI.0000000000003395.
    >> Share

    January 2024
  70. TURK T, Labarile M, Braun DL, Rauch A, et al
    CHARACTERIZATION AND DETERMINANTS OF LONG-TERM IMMUNE RECOVERY UNDER SUPPRESSIVE ANTIRETROVIRAL THERAPY.
    J Acquir Immune Defic Syndr. 2024 Jan 24. doi: 10.1097/QAI.0000000000003388.
    >> Share

  71. BUNGE K, Balkus JE, Fairlie L, Mayo AJ, et al
    DELIVER: A Safety Study of a Dapivirine Vaginal Ring and Oral PrEP for the Prevention of HIV During Pregnancy.
    J Acquir Immune Defic Syndr. 2024;95:65-73.
    >> Share

    December 2023
  72. BROOKS KM, Pau AK, Swaim D, Bunn HT, et al
    Pharmacokinetics, Safety, and Tolerability of Once-Daily Darunavir With Cobicistat and Weekly Isoniazid/Rifapentine.
    J Acquir Immune Defic Syndr. 2023;94:468-473.
    >> Share

  73. FAIRLIE L, Sawry S, Pals S, Sherman G, et al
    More Frequent HIV Viral Load Testing With Point-Of-Care Tests Detects Elevated Viral Load Earlier in Postpartum HIV-Positive Women in a Randomized Controlled Trial in Two Clinics in Johannesburg, South Africa.
    J Acquir Immune Defic Syndr. 2023;94:412-420.
    >> Share

  74. HECHTER RC, Zhou H, Leyden WA, Yuan Q, et al
    Fracture Risk and Association With TDF Use Among People With HIV in Large Integrated Health Systems.
    J Acquir Immune Defic Syndr. 2023;94:341-348.
    >> Share

    November 2023
  75. ARNOLD EM, Kamal S, Rotheram-Borus MJ, Bridges SK, et al
    Factors Associated with Antiretroviral Adherence among Youth Living with HIV.
    J Acquir Immune Defic Syndr. 2023 Nov 17. doi: 10.1097/QAI.0000000000003345.
    >> Share

  76. LIEGEON G, Brun A, Hamet G, Zeggagh J, et al
    Incidence and Management of Complex Kidney Situations Among On-demand and Daily HIV Pre-exposure Prophylaxis Users.
    J Acquir Immune Defic Syndr. 2023 Nov 16. doi: 10.1097/QAI.0000000000003346.
    >> Share

  77. JIANG W, Ronen K, Osborn L, Drake AL, et al
    HIV viral load patterns and risk factors among women in prevention of mother-to-child transmission (PMTCT) programs to inform differentiated service delivery (DSD).
    J Acquir Immune Defic Syndr. 2023 Nov 15. doi: 10.1097/QAI.0000000000003352.
    >> Share

  78. LANTING VR, Oosterhof P, Moha DA, van Heerde R, et al
    Switching to doravirine in cART experienced patients: An effective and highly tolerated option with substantial cost savings.
    J Acquir Immune Defic Syndr. 2023 Nov 10. doi: 10.1097/QAI.0000000000003337.
    >> Share

  79. BOUSMAH MA, Protopopescu C, Mpoudi-Etame M, Omgba Bassega P, et al
    Improvements in Patient-Reported Outcomes Following Initiation of Dolutegravir-Based or Low-Dose Efavirenz-Based First-Line Antiretroviral Therapy: A Four-Year Longitudinal Analysis in Cameroon (NAMSAL ANRS 12313 Trial).
    J Acquir Immune Defic Syndr. 2023;94:262-272.
    >> Share

  80. FERNVIK E, Sierra Madero J, Espinosa N, Gulminetti R, et al
    Impact of Treatment Adherence on Efficacy of Dolutegravir + Lamivudine and Dolutegravir + Tenofovir Disoproxil Fumarate/Emtricitabine: Pooled Week 144 Analysis of the GEMINI-1 and GEMINI-2 Clinical Studies.
    J Acquir Immune Defic Syndr. 2023;94:e9-e12.
    >> Share

    October 2023
  81. KATAREY D, Tan Y, Mourad A, Potts JR, et al
    Non-viral Liver Disease Burden in People Living with HIV and elevated transaminases: A Cross-sectional Study.
    J Acquir Immune Defic Syndr. 2023 Oct 12. doi: 10.1097/QAI.0000000000003322.
    >> Share

    September 2023
  82. GEIGER K, Patil A, Budhathoki C, Dooley KE, et al
    Successful MDR-TB Treatment Without HIV Viral Suppression: A Missed Opportunity.
    J Acquir Immune Defic Syndr. 2023 Sep 28. doi: 10.1097/QAI.0000000000003268.
    >> Share

  83. CHI BH, Saidi F, Graybill LA, Phanga T, et al
    A patient-centered, combination intervention to support adherence to HIV pre-exposure prophylaxis during pregnancy and breastfeeding: a randomized pilot study in Malawi.
    J Acquir Immune Defic Syndr. 2023 Sep 28. doi: 10.1097/QAI.0000000000003309.
    >> Share

  84. POLISENO M, Mazzitelli M, Narducci A, Ferrara SM, et al
    Doravirine plus Integrase Strand Transfer Inhibitors as a two-drugs treatment-switch strategy in PLWH: the real-life DORINI multicentric cohort study.
    J Acquir Immune Defic Syndr. 2023 Sep 27. doi: 10.1097/QAI.0000000000003248.
    >> Share

  85. BUNGE K, Balkus JE, Fairlie L, Mayo AJ, et al
    DELIVER: A Safety Study of a Dapivirine Vaginal Ring and Oral PrEP for the Prevention of HIV During Pregnancy.
    J Acquir Immune Defic Syndr. 2023 Sep 27. doi: 10.1097/QAI.0000000000003312.
    >> Share

    August 2023
  86. BOUSMAH MA, Protopopescu C, Mpoudi-Etame M, Bassega PO, et al
    Improvements in patient-reported outcomes following initiation of dolutegravir- or low-dose efavirenz-based first-line antiretroviral therapy: A four-year longitudinal analysis in Cameroon (NAMSAL ANRS 12313 trial).
    J Acquir Immune Defic Syndr. 2023 Aug 14. doi: 10.1097/QAI.0000000000003273.
    >> Share

    June 2023
  87. REIS AO, Rocco Suassuna JH, Cunha CB, Portela EN, et al
    Evaluation of glomerular filtration rate trends in people living with HIV corrected by the baseline glomerular filtration rate.
    J Acquir Immune Defic Syndr. 2023 Jun 1. doi: 10.1097/QAI.0000000000003232.
    >> Share

    May 2023
  88. VHEMBO T, Baltrusaitis K, Tierney C, Owor M, et al
    Bone and renal health in infants with or without breastmilk exposure to tenofovir-based maternal antiretroviral treatment in the PROMISE randomized trial.
    J Acquir Immune Defic Syndr. 2023 May 15. doi: 10.1097/QAI.0000000000003218.
    >> Share

    April 2023
  89. DORWARD J, Sookrajh Y, Lessells R, Bulo E, et al
    Point-of-care viral load testing to manage HIV viraemia during the rollout of dolutegravir-based ART in South Africa: a randomised feasibility study (POwER).
    J Acquir Immune Defic Syndr. 2023 Apr 19. doi: 10.1097/QAI.0000000000003212.
    >> Share

    March 2023
  90. JENNINGS L, Ferraris CM, Castillo-Mancilla JR, Robbins RN, et al
    Comparing predictive ability of two objective adherence measures in a community-based cohort on antiretroviral therapy in South Africa: tenofovir diphosphate concentrations and electronic adherence monitors.
    J Acquir Immune Defic Syndr. 2023 Mar 27. doi: 10.1097/QAI.0000000000003198.
    >> Share

  91. QIAN Y, Wang L, Xing Y, Yin L, et al
    Tenofovir concentration is not enough in intraocular tissues of patients with HIV-infection.
    J Acquir Immune Defic Syndr. 2023 Mar 1. doi: 10.1097/QAI.0000000000003171.
    >> Share

    February 2023
  92. ELBUR AI, Ghebremichael M, Konkle-Parker D, Jones DL, et al
    Trajectories of Antiretroviral Therapy Adherence and Virologic Failure in Women with HIV in the United States.
    J Acquir Immune Defic Syndr. 2023 Feb 20. doi: 10.1097/QAI.0000000000003174.
    >> Share

  93. HICKEY MD, Wafula E, Ogachi SM, Ojwando H, et al
    Weight change following switch to dolutegravir for HIV treatment in rural Kenya during country roll-out.
    J Acquir Immune Defic Syndr. 2023 Feb 14. doi: 10.1097/QAI.0000000000003173.
    >> Share

  94. VAN PRAET JT, Serrien B, Ausselet N, Darcis G, et al
    Dynamics of weight change after initiation of contemporaneous antiretroviral therapy in treatment-naive HIV-1 patients: results from the Belgian HIV Cohort 2015-2021.
    J Acquir Immune Defic Syndr. 2023 Feb 14. doi: 10.1097/QAI.0000000000003175.
    >> Share

  95. JACOBS TG, Mumbiro V, Chitsamatanga M, Namuziya N, et al
    Suboptimal lopinavir exposure in infants on rifampicin treatment receiving double-dosed or semi-superboosted lopinavir/ritonavir: time for a change.
    J Acquir Immune Defic Syndr. 2023 Feb 1. doi: 10.1097/QAI.0000000000003168.
    >> Share

    January 2023
  96. KEENE CM, Cassidy T, Zhao Y, Griesel R, et al
    Recycling tenofovir in second-line antiretroviral treatment with dolutegravir: outcomes and viral load trajectories to 72 weeks.
    J Acquir Immune Defic Syndr. 2023 Jan 25. doi: 10.1097/QAI.0000000000003157.
    >> Share

  97. CHAPIN-BARDALES J, Haaland R, Martin A, Holder A, et al
    HIV pre-exposure prophylaxis persistence and adherence among men who have sex with men in 4 U.S. cities.
    J Acquir Immune Defic Syndr. 2023 Jan 9. doi: 10.1097/QAI.0000000000003160.
    >> Share

  98. GANESAN K, Mwesigwa R, Dear N, Esber AL, et al
    EPIDEMIOLOGY OF TUBERCULOSIS AMONG PEOPLE LIVING WITH HIV IN THE AFRICAN COHORT STUDY FROM 2013-2021.
    J Acquir Immune Defic Syndr. 2023 Jan 3. doi: 10.1097/QAI.0000000000003152.
    >> Share

    December 2022

  99. Efficacy and Safety of a Simplified Lamivudine Plus Dolutegravir Dual Therapy in HIV-1-Infected Patients: A Multicenter Cohort Study in China: Erratum.
    J Acquir Immune Defic Syndr. 2022;91:516.
    >> Share

  100. AJIBOLA G, Maswabi K, Hughes MD, Bennett K, et al
    Long-term clinical, immunologic, and virologic outcomes among early-treated children with HIV in Botswana: a nonrandomized controlled clinical trial.
    J Acquir Immune Defic Syndr. 2022 Dec 12. doi: 10.1097/QAI.0000000000003147.
    >> Share

  101. SAROWAR A, Coffin CS, Fung S, Wong A, et al
    Brief Report: Effect of Antiretroviral Switch From Tenofovir Disoproxil fumarate to Tenofovir Alafenamide on Alanine Aminotransferase, Lipid Profiles, and Renal Function in HIV/HBV-Coinfected Individuals in a Nationwide Canadian Study.
    J Acquir Immune Defic Syndr. 2022;91:368-372.
    >> Share

    November 2022
  102. MILLER AP, Shoptaw S, Moucheraud C, Mvududu R, et al
    Recent alcohol use is associated with increased Pre-exposure Prophylaxis (PrEP) continuation and adherence among pregnant and post-partum women in South Africa.
    J Acquir Immune Defic Syndr. 2022 Nov 21. doi: 10.1097/QAI.0000000000003133.
    >> Share

  103. PIERRE DE VILLARTAY J, Pannier E, Sibiude J, Frange P, et al
    T Cell Receptor alpha repertoire diversity at birth after in utero exposure to HIV integrase strand-transfer inhibitors.
    J Acquir Immune Defic Syndr. 2022 Nov 7. pii: 00126334-990000000-00149.
    >> Share

    October 2022
  104. COLEMAN JS, Diniz CP, Fuchs EJ, Marzinke MA, et al
    Interaction of Depot Medroxyprogesterone Acetate and Tenofovir Disoproxil Fumarate/Emtricitabine on Peripheral Blood Mononuclear Cells and Cervical Tissue Susceptibility to HIV Infection and Pharmacokinetics.
    J Acquir Immune Defic Syndr. 2022 Oct 13. pii: 00126334-990000000-00134.
    >> Share

  105. MELVIN AJ, Yee KL, Gray KP, Yedla M, et al
    Pharmacokinetics, tolerability and safety of doravirine and doravirine/lamivudine/tenofovir disoproxil fumarate fixed dose combination tablets in adolescents living with HIV: Week 24 results from IMPAACT 2014.
    J Acquir Immune Defic Syndr. 2022 Oct 10. pii: 00126334-990000000-00136.
    >> Share

  106. ZHONG M, Chen C, Hu Y, Zou M, et al
    Efficacy and Safety of a Simplified Lamivudine Plus Dolutegravir Dual Therapy in HIV-1-Infected Patients: A Multicenter Cohort Study in China.
    J Acquir Immune Defic Syndr. 2022;91.
    >> Share

  107. YAN D, Wang Z, Wang Y, He S, et al
    Performance of Creatinine- and Cystatin C-Based Equations for Glomerular Filtration Rate Estimation in HIV-1-Infected Individuals Receiving Dolutegravir + Tenofovir Disoproxil Fumarate + Lamivudine as Initial Antiretroviral Therapy: A Retrospective Ob
    J Acquir Immune Defic Syndr. 2022;91.
    >> Share

  108. ZHAO F, Rao M, Chen W, Cai K, et al
    Dolutegravir Plus Lamivudine Dual-Drug Regimen in Treatment-Naive HIV-1-Infected Patients With High-Level Viral Load: Preliminary Data From the Real World.
    J Acquir Immune Defic Syndr. 2022;91.
    >> Share

  109. SUN L, He Y, Xu L, Zhao F, et al
    Higher Risk of Dyslipidemia With Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide than Efavirenz, Lamivudine, and Tenofovir Disoproxil Fumarate Among Antiretroviral-Naive People Living With HIV in China.
    J Acquir Immune Defic Syndr. 2022;91.
    >> Share

  110. TONGTONG Y, Shenghua H, Yin W, Lin C, et al
    Effectiveness and Safety of Dolutegravir Versus Efavirenz-Based Antiviral Regimen in People Living With HIV-1 in Sichuan Province of China: A Real-World Study.
    J Acquir Immune Defic Syndr. 2022;91.
    >> Share

  111. DUMCHEV K, Kiriazova T, Riabokon S, Shost A, et al
    Comparative Clinical Outcomes With Scale-up of Dolutegravir as First-Line Antiretroviral Therapy in Ukraine.
    J Acquir Immune Defic Syndr. 2022;91:197-209.
    >> Share

    September 2022
  112. NEVREKAR N, Butler K, Shapiro DE, Atuhaire P, et al
    Self-Reported Antiretroviral Adherence: Association with Maternal Viral Load Suppression in Postpartum Women Living with HIV-1 from Promoting Maternal and Infant Survival Everywhere (PROMISE), a Randomized Controlled Trial in Sub-Saharan Africa and In
    J Acquir Immune Defic Syndr. 2022 Sep 28. pii: 00126334-990000000-00117.
    >> Share

  113. CHAMMARTIN F, Darling K, Abela IA, Battegay M, et al
    CD4:CD8 ratio and CD8 cell count and their prognostic relevance for coronary heart disease events and stroke in antiretroviral treated individuals: The Swiss HIV Cohort Study.
    J Acquir Immune Defic Syndr. 2022 Sep 23. pii: 00126334-990000000-00116.
    >> Share

  114. PALELLA FJ, Hou Q, Li J, Mahnken J, et al
    Weight gain and metabolic effects in persons with HIV who switch to ART regimens containing integrase inhibitors or tenofovir alafenamide.
    J Acquir Immune Defic Syndr. 2022 Sep 23. pii: 00126334-990000000-00121.
    >> Share

  115. OPSTEEN S, Moylan D, Taiwo BO, Robertson KR, et al
    Intracellular cystatin B levels are altered in HIV-infected participants with respect to neurocognitive status and anti-retroviral therapy.
    J Acquir Immune Defic Syndr. 2022 Sep 9. pii: 00126334-990000000-00107.
    >> Share

  116. MORRIS SR, Jain S, Blumenthal J, Bolan R, et al
    Randomized Trial of Individualized Texting for Adherence Building (iTAB) plus Motivational Interviewing for PrEP Adherence in Transgender Individuals (The iM-PrEPT Study).
    J Acquir Immune Defic Syndr. 2022 Sep 8. pii: 00126334-990000000-00110.
    >> Share

  117. SOLANKE T, Kamau F, Esterhuizen T, Maartens G, et al
    Concentrations of Efavirenz, Tenofovir, and Emtricitabine in Obesity: A Cross-Sectional Study.
    J Acquir Immune Defic Syndr. 2022;91:101-108.
    >> Share

  118. MOLINA JM, Yazdanpanah Y, Afani Saud A, Bettacchi C, et al
    Brief Report: Efficacy and Safety of Oral Islatravir Once Daily in Combination With Doravirine Through 96 Weeks for Treatment-Naive Adults With HIV-1 Infection Receiving Initial Treatment With Islatravir, Doravirine, and Lamivudine.
    J Acquir Immune Defic Syndr. 2022;91:68-72.
    >> Share

  119. BEESHAM I, Mansoor LE, Joseph Davey DL, Palanee-Phillips T, et al
    Brief Report: Quantifiable Plasma Tenofovir Among South African Women Using Daily Oral Pre-exposure Prophylaxis During the ECHO Trial.
    J Acquir Immune Defic Syndr. 2022;91:26-30.
    >> Share

  120. COUTINHO CM, Warshaw MG, Duarte G, Stek A, et al
    Effects of initiating raltegravir-based versus efavirenz-based antiretroviral regimens during pregnancy on weight changes and perinatal outcomes: NICHD P1081.
    J Acquir Immune Defic Syndr. 2022 Sep 1. pii: 00126334-990000000-00100.
    >> Share

    August 2022
  121. CALZA L, Bon I, Pensalfine G, Vitale S, et al
    CHANGES IN SERUM INFLAMMATORY MARKERS IN ANTIRETROVIRAL THERAPY-NAIVE HIV-INFECTED PATIENTS STARTING DOLUTEGRAVIR/LAMIVUDINE OR TENOFOVIR ALAFENAMIDE/EMTRICITABINE/BICTEGRAVIR.
    J Acquir Immune Defic Syndr. 2022 Aug 18. pii: 00126334-990000000-00095.
    >> Share

  122. DRAGONI F, Rossetti B, Lombardi F, Raffaelli CS, et al
    Dynamics of total and intact HIV-1 DNA in virologically suppressed patients switching to DTG- or ATV-based dual therapy.
    J Acquir Immune Defic Syndr. 2022 Aug 15. pii: 00126334-990000000-00092.
    >> Share

  123. NEMATADZIRA TG, Murnane PM, Odiase OJ, Bacchetti P, et al
    ANTIRETROVIRAL THERAPY ADHERENCE DURING AND POST BREASTFEEDING CESSATION MEASURED BY TENOFOVIR LEVELS IN HAIR.
    J Acquir Immune Defic Syndr. 2022 Aug 11. pii: 00126334-990000000-00086.
    >> Share

  124. WEISS F, von Both U, Rack-Hoch A, Sollinger F, et al
    HIV-Positive and Breastfeeding in High-Income Settings: 5-year Experience from a Perinatal Center in Germany.
    J Acquir Immune Defic Syndr. 2022 Aug 9. pii: 00126334-990000000-00088.
    >> Share

  125. ESBER A, Dear N, Shah N, Kibuuka H, et al
    Virologic impact of the dolutegravir transition: prospective results from the multinational African Cohort Study.
    J Acquir Immune Defic Syndr. 2022 Aug 3. pii: 00126334-990000000-00084.
    >> Share

    May 2022
  126. KIWEEWA FM, Tierney C, Butler K, Peters MG, et al
    Impact of Antiretroviral Regimen on Pregnancy and Infant Outcomes in Women with HIV/ HBV Co-infection.
    J Acquir Immune Defic Syndr. 2022 May 27. pii: 00126334-990000000-00050.
    >> Share

  127. KHERABI Y, de Castro N, Sellier PO, Hamet G, et al
    Efficacy and safety of efavirenz, raltegravir and dolutegravir in HIV-1/TB co-infection. A multicenter retrospective cohort study in France.
    J Acquir Immune Defic Syndr. 2022 May 26. pii: 00126334-990000000-00052.
    >> Share

    April 2022
  128. CANNON CA, Ramchandani MS, Buskin S, Dombrowski J, et al
    Previous Pre-Exposure Prophylaxis Use Among Men Who Have Sex with Men Newly Diagnosed with HIV Infection in King County, Washington.
    J Acquir Immune Defic Syndr. 2022 Apr 29. pii: 00126334-990000000-00035.
    >> Share

  129. SCHROTER J, Anelone AJN, de Boer RJ
    Quantification of CD4 Recovery in Early-Treated Infants Living With HIV.
    J Acquir Immune Defic Syndr. 2022;89:546-557.
    >> Share

    March 2022
  130. PATHELA P, Qasmieh S, Gandhi M, Rozen E, et al
    Use of remnant specimens to assess use of HIV pre-exposure prophylaxis (PrEP) among populations with risk for HIV infection: A novel approach.
    J Acquir Immune Defic Syndr. 2022 Mar 31. pii: 00126334-990000000-00015.
    >> Share

  131. MENG W, Chen M, Song Y, Zhang H, et al
    Prevalence and Risk Factors of Low Bone Mineral Density in HIV/AIDS Patients: a Chinese Cross-sectional Study.
    J Acquir Immune Defic Syndr. 2022 Mar 22. pii: 00126334-990000000-00011.
    >> Share

    December 2021
  132. DIJKSTRA S, Hofstra LM, Mudrikova T, Wensing AMJ, et al
    Lower incidence of HIV-1 blips observed during integrase inhibitor-based combination antiretroviral therapy.
    J Acquir Immune Defic Syndr. 2021 Dec 24. pii: 00126334-900000000-95731.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016